Rianne Rijneveld

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Deepak M.W. Balak, Martijn B. A. van Doorn, Robert D. Arbeit et al. · Clinical Immunology · 2016 · 93 citations

Inflammation, Toll-like Receptor 7, Anti-inflammatory +13

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Tessa Niemeyer‐van der Kolk, Hein van der Wall, G. Hogendoorn et al. · Clinical and Translational Science · 2020 · 44 citations · Full text

Asthma, Drug Hypersensitivity, Antibiotics +15

Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology

M. Rijsbergen, Tessa Niemeyer‐van der Kolk, Rianne Rijneveld et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 32 citations · Full text

Topical ionic contra‐viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts

Tessa Niemeyer‐van der Kolk, Marlous R. Dillingh, Rianne Rijneveld et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 22 citations · Full text

Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions

M. Rijsbergen, Rianne Rijneveld, M. Todd et al. · British Journal of Clinical Pharmacology · 2019 · 19 citations · Full text